Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

61. Denosumab (Prolia) and osteoporosis: an increasingly unfavourable harm-benefit balance

Denosumab (Prolia) and osteoporosis: an increasingly unfavourable harm-benefit balance Prescrire IN ENGLISH - Spotlight ''Denosumab (Prolia°) and osteoporosis: an increasingly unfavourable harm-benefit balance '', 1 November 2018 {1} {1} {1} | | > > > Denosumab (Prolia°) and osteoporosis: an increasingly unfavourable harm-benefit balance Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |    (...) |   |   |  Spotlight Denosumab (Prolia°) and osteoporosis: an increasingly unfavourable harm-benefit balance Reports of sometimes serious adverse effects tilt the harm-benefit balance of denosumab in the treatment of osteoporosis. Denosumab is authorised in some cases of osteoporosis and bone metastases. As expected from the pre-market evaluation of denosumab, reports of adverse reactions related to disruption of the immune system attributed to denosumab are accumulating. To date

2018 Prescrire

62. Association Between Cataract and Risks of Osteoporosis and Fracture: A Nationwide Cohort Study (Abstract)

Association Between Cataract and Risks of Osteoporosis and Fracture: A Nationwide Cohort Study To evaluate the association between cataract and cataract surgery and risks of osteoporosis and fracture.Nationwide population-based retrospective cohort study.Taiwan's National Health Insurance Research Database.Individuals with (n=57,972) and without (n=57,972) cataracts.Individuals with and without cataracts were matched 1:1 for age, sex, and index year. Those with cataracts were further divided (...) into cataract surgery and nonsurgery groups. Incidences and hazard ratios (HR) for risks of developing osteoporosis and fracture were calculated using Cox proportional hazard regression models.During mean follow-up of 6.4 years, 17,450 participants with cataracts and 12,627 without developed osteoporosis or fractures. Having cataracts was significantly associated with risk of developing osteoporosis or fracture (adjusted HR (aHR) = 1.29, 95% confidence interval (CI) = 1.25-1.32, p < .001). In analyses

2018 EvidenceUpdates

63. Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial Full Text available with Trip Pro

Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial Denosumab (DNM) is a fully human monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand (RANKL) that has been licensed for the treatment of different types of osteoporosis. However, the prospective data for the evaluation of DNM efficacy on transfusion-dependent thalassemia (TDT)-induced osteoporosis are rather limited. Thus, we (...) conducted a randomized, placebo-controlled, double-blind, phase 2b clinical trial to evaluate DNM in TDT osteoporosis. Patients were assigned to receive either 60 mg DNM (n = 32) or placebo (n = 31) subcutaneously on day 0 and 180 during a total of 12 months of follow-up. The percentage increase of L1-L4 bone mineral density was higher in the DNM group than the placebo group (5.92% ± 5.25% vs 2.92% ± 5.56%, respectively; P = .043), whereas the advantage of DNM regarding wrist bone mineral density

2018 Blood advances Controlled trial quality: predicted high

64. Osteoporosis

Osteoporosis Osteoporosis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Osteoporosis Last reviewed: February 2019 Last updated: October 2018 Summary Asymptomatic until fracture occurs. Diagnosis based on history of prior fragility fracture or low bone mineral density, which is defined as a T-score ≤-2.5. Screening is based on individual risk factors, including female sex, maternal history of fragility fracture (...) /osteoporosis, older age, low body mass index (<20 to 25 kg/m²), body weight <58 kg, weight loss of >10% of body weight, androgen deprivation treatment (in males), aromatase inhibitor treatment (in females), corticosteroid use, tobacco use, and kidney stone disease. Fall prevention is first-line therapy. Bisphosphonates are first-line pharmacological therapy for postmenopausal women and men. In postmenopausal women, oestrogen is considered only for those at high risk for whom non-oestrogen medicines

2018 BMJ Best Practice

65. Correlation between skin and bone parameters in women with postmenopausal osteoporosis: A systematic review Full Text available with Trip Pro

Correlation between skin and bone parameters in women with postmenopausal osteoporosis: A systematic review Skin and bone share similarities in terms of biochemical composition.Some authors have hypothesized that their properties could evolve concomitantly with age, allowing the estimation of the parameters of one from those of the other.We performed a systematic review of studies reporting the correlation between skin and bone parameters in women with postmenopausal osteoporosis.Fourteen

2018 EFORT open reviews

66. Osteoporosis

Osteoporosis Top results for osteoporosis - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for osteoporosis The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

67. Osteoanabolic Agents for Osteoporosis Full Text available with Trip Pro

Osteoanabolic Agents for Osteoporosis Medications for osteoporosis are classified as either antiresorptive or anabolic. Whereas antiresorptive agents prevent bone resorption, anabolic agents promote new bone formation. Anabolics should be considered in individuals with severe osteoporosis, failure of alternative osteoporosis agents, intolerability or contraindications to other osteoporosis agents, and glucocorticoid-induced osteoporosis. There are currently two approved anabolic therapies

2018 Journal of the Endocrine Society

68. Osteoporosis to Prevent Fractures: Screening

Osteoporosis to Prevent Fractures: Screening Final Update Summary: Osteoporosis to Prevent Fractures: Screening - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 11/16/2018 6:27:19 PM You are here: Final Summary Osteoporosis to Prevent Fractures: Screening Osteoporosis to Prevent Fractures: Screening Release Date: June 2018 Recommendation Summary Population Recommendation Grade Women 65 years and older The USPSTF recommends screening (...) for osteoporosis with bone measurement testing to prevent osteoporotic fractures in women 65 years and older. Postmenopausal women younger than 65 years at increased risk of osteoporosis The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in postmenopausal women younger than 65 years who are at increased risk of osteoporosis, as determined by a formal clinical risk assessment tool. See the for information on risk assessment. Men The USPSTF concludes

2018 U.S. Preventive Services Task Force

69. Osteoporosis

Osteoporosis Evidence Maps - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4

2018 Trip Evidence Maps

70. Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement. Full Text available with Trip Pro

Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement. By 2020, approximately 12.3 million individuals in the United States older than 50 years are expected to have osteoporosis. Osteoporotic fractures, particularly hip fractures, are associated with limitations in ambulation, chronic pain and disability, loss of independence, and decreased quality of life, and 21% to 30% of patients who experience a hip fracture die within 1 year (...) . The prevalence of primary osteoporosis (ie, osteoporosis without underlying disease) increases with age and differs by race/ethnicity. With the aging of the US population, the potential preventable burden is likely to increase in future years.To update the 2011 US Preventive Services Task Force (USPSTF) recommendation on screening for osteoporosis.The USPSTF reviewed the evidence on screening for and treatment of osteoporotic fractures in men and women, as well as risk assessment tools, screening intervals

2018 JAMA

71. How Would You Manage This Patient With Osteoporosis?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. (Abstract)

How Would You Manage This Patient With Osteoporosis?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Osteoporosis is a skeletal disorder characterized by reduced bone strength that increases the risk for fracture. Approximately 10 million men and women in the United States have osteoporosis, and more than 2 million osteoporosis-related fractures occur annually. In 2016, the American Association of Clinical Endocrinologists issued the "Clinical Practice Guideline (...) for the Diagnosis and Treatment of Postmenopausal Osteoporosis," and in 2017, the American College of Physicians issued the guideline "Treatment of Low Bone Density or Osteoporosis to Prevent Fracture in Men and Women." Both guidelines agree that patients diagnosed with osteoporosis should be treated with an antiresorptive agent, such as alendronate, that has been shown to reduce hip and vertebral fractures. However, there is no consensus on how long patients with osteoporosis should be treated and whether bone

2018 Annals of Internal Medicine

72. Comparative assessment of fracture risk among osteoporosis and osteopenia patients: a cross-sectional study Full Text available with Trip Pro

Comparative assessment of fracture risk among osteoporosis and osteopenia patients: a cross-sectional study Both osteoporosis and osteopenia remain worldwide public health concerns. They both lead to bone fractures, which can lead to disability and burden on those who are afflicted.To assess and compare fracture risk between these two groups of patients.Our cross-sectional study included 82 patients (46 with osteoporosis and 36 with osteopenia) with an average age of 63±9.33 years, who received (...) treatment at the Clinic for Medical Rehabilitation, Clinical Center of Vojvodina in Novi Sad, Serbia. The assessment of the fracture risk was executed by applying the Fracture Assessment Risk (FRAX) index (an algorithm developed by the World Health Organization) based on clinical fracture risks or combination of clinical fracture risks and bone mineral density.Patients with osteoporosis had significantly higher risk of major fracture compared to patients with osteopenia (p<0.01). Results from FRAX index

2018 Open access rheumatology : research and reviews

73. Common osteoporosis drugs may prevent breast cancer spreading to bone

Common osteoporosis drugs may prevent breast cancer spreading to bone Common osteoporosis drugs may prevent breast cancer spreading to bone Discover Portal Discover Portal Common osteoporosis drugs may prevent breast cancer spreading to bone Published on 13 March 2018 doi: Drugs commonly prescribed to prevent bone thinning probably help prevent the spread of early breast cancer to the bones in a few women, when taken in addition to standard cancer therapies. However, the overall benefits may

2018 NIHR Dissemination Centre

74. Cement injections to treat spinal compression fractures from osteoporosis can reduce short term pain

Cement injections to treat spinal compression fractures from osteoporosis can reduce short term pain Cement injections to treat spinal compression fractures from osteoporosis can reduce short term pain Discover Portal Discover Portal Cement injections to treat spinal compression fractures from osteoporosis can reduce short term pain Published on 13 December 2016 doi: Injecting cement into osteoporotic spinal fractures within six weeks reduces pain in the first few months and disability six (...) centres. Share your views on the research. Why was this study needed? Worldwide, an estimated 1.4 million people with osteoporosis experience vertebral fractures. Most osteoporotic vertebral fractures are treated conservatively with painkillers, bed rest and mobility exercises as function improves. However, painkillers and prolonged bed rest can both have adverse effects in older people. Vertebroplasty involves injecting special cement into the broken vertebrae to relieve pain and strengthen the bone

2018 NIHR Dissemination Centre

75. Prompts for GPs may improve diagnosis and treatment of osteoporosis

Prompts for GPs may improve diagnosis and treatment of osteoporosis Prompts for GPs may improve diagnosis and treatment of osteoporosis Discover Portal Discover Portal Prompts for GPs may improve diagnosis and treatment of osteoporosis Published on 30 August 2016 doi: Prompts for GPs with education and reminders for patients may improve “guideline consistent behaviour” and diagnosis and treatment of osteoporosis. Similar techniques aimed at improving GP management of other common (...) benefit more. Share your views on the research. Why was this study needed? Musculoskeletal conditions such as osteoporosis, back pain and arthritis are common causes of pain and disability in the UK. One in six adults lives with a chronic musculoskeletal condition. Every year, over 20% of people consult their GP about musculoskeletal problems. Musculoskeletal conditions are a major cause of health system spending. In 2009-10, the NHS spent £4.76 billion in this area; this is more than £13 million

2018 NIHR Dissemination Centre

76. Sleep apnea is not a significant risk factor for osteoporosis in male adults: a meta-analysis

Sleep apnea is not a significant risk factor for osteoporosis in male adults: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2018 PROSPERO

77. Pulsed electromagnetic fields (PEMFs) for preventing and treating osteoporosis: a systematic review and meta-analysis

Pulsed electromagnetic fields (PEMFs) for preventing and treating osteoporosis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2018 PROSPERO

78. Long-term use of bisphosphonates in postmenopausal women with osteopenia versus osteoporosis: a systematic review and network meta-analysis

Long-term use of bisphosphonates in postmenopausal women with osteopenia versus osteoporosis: a systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

79. Effects of milk and dairy products in the prevention of osteoporosis and osteoporotic fractures: a systematic review and an update metanalysis

Effects of milk and dairy products in the prevention of osteoporosis and osteoporotic fractures: a systematic review and an update metanalysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

80. Comparative efficacy of different pharmacological agents in patients with glucocorticoid-induced osteoporosis: an overview and network meta-analysis

Comparative efficacy of different pharmacological agents in patients with glucocorticoid-induced osteoporosis: an overview and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2018 PROSPERO